Marshall Wace
FULC icon

Marshall Wace’s Fulcrum Therapeutics FULC Stock Holding History

Marshall Wace’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-102,921
Closed -$1.16M – 3378
2025
Q4 		$1.16M Buy
+102,921
New +$1.05M ﹤0.01% 1854
2024
Q3 		– Sell
-333,161
Closed -$2.07M – 2664
2024
Q2 		$2.07M Buy
333,161
+107,588
+48% +$815K ﹤0.01% 1354
2024
Q1 		$2.13M Sell
225,573
-279,529
-55% -$2.5M ﹤0.01% 1333
2023
Q4 		$3.41M Sell
505,102
-543,544
-52% -$2.41M 0.01% 1043
2023
Q3 		$4.66M Buy
1,048,646
+1,031,246
+5,927% +$4.51M 0.01% 893
2023
Q2 		$57.4K Sell
17,400
-103,600
-86% -$304K ﹤0.01% 2365
2023
Q1 		$345K Buy
121,000
+105,474
+679% +$945K ﹤0.01% 2246
2022
Q4 		$113K Sell
15,526
-4,589
-23% -$29.9K ﹤0.01% 2776
2022
Q3 		$162K Buy
+20,115
New +$144K ﹤0.01% 3127
2022
Q1 		– Sell
-13,513
Closed -$239K – 3562
2021
Q4 		$239K Sell
13,513
-138,176
-91% -$2.74M ﹤0.01% 3103
2021
Q3 		$4.28M Buy
+151,689
New +$2.87M 0.02% 1029

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marshall Wace's FULC Position: Q1 2026 in Review

Marshall Wace sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 102,921 shares — an estimated $1.16M sold.

Marshall Wace first reported a position in FULC in Q3 2021 and held it in 11 quarters. The position peaked at $4.66M in Q3 2023. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Marshall Wace reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 102,921 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.16M.
  • Marshall Wace first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 11 quarters.
  • Marshall Wace's Fulcrum Therapeutics position peaked at $4.66M in Q3 2023.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.